Author

R. M. Suciu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

C. L. Henry· 2 shared M. J. Niphakis· 2 shared N. Ngo· 2 shared A. Inguva· 1 shared A. J. Firestone· 1 shared A. Long· 1 shared A. M. Gregus· 1 shared A. M. Pinto· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPhysiology

C. L. Henry

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

PhysiologybioRxivPreprintAug 8, 2023

Inflammation causes insulin resistance via interferon regulatory factor 3 (IRF3)-mediated reduction in FAHFA levels

S. Yan, A. Santoro, M. J. Niphakis…·E. D. Rosen

This study identifies the IRF3/AIG1 axis in adipocytes as a mechanism linking obesity-induced inflammation to insulin resistance and suggests AIG1 inhibition as a therapeutic approach.

DOI 10.1101/2023.08.08.552481

mousebulk RNA-seq

𝕏 PostBluesky

BiochemistrybioRxivPreprintJun 17, 2020

Hydrazines as versatile chemical biology probes and drug-discovery tools for cofactor-dependent enzymes

Z. Lin, X. Wang, K. A. Bustin…·M. L. Matthews

This paper introduces hydrazine-based chemoproteomic probes to target cofactor-dependent enzymes, enabling enzyme discovery and drug development through diverse functional profiling.

DOI 10.1101/2020.06.17.154864

experimental assaydrug response / drug discovery

𝕏 PostBluesky

Cancer BiologybioRxivMay 21, 2020

ABHD17 enzymes regulate dynamic plasma membrane palmitoylation and N-Ras-dependent cancer growth

J. R. Remsberg, R. M. Suciu, N. A. Zambetti…·B. F. Cravatt

This study identifies ABD957, a selective ABHD17 inhibitor, which disrupts N-Ras depalmitoylation and inhibits NRAS-mutant AML growth, suggesting potential as a targeted therapy.

DOI 10.1038/s41589-021-00785-8

humanproteomics

𝕏 PostBluesky